Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/59519
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Santamaría, Carlos | - |
dc.contributor.author | Chillón, M. del Carmen | - |
dc.contributor.author | García-Sanz, Ramón | - |
dc.contributor.author | Caballero, Maria Dolores | - |
dc.contributor.author | Mateos, Maria Victoria | - |
dc.contributor.author | Sarasquete, María Eugenia | - |
dc.contributor.author | Díaz-Mediavilla, J. | - |
dc.contributor.author | San Miguel, Jesús F. | - |
dc.contributor.author | González, Marcos | - |
dc.date.accessioned | 2012-11-06T09:35:42Z | - |
dc.date.available | 2012-11-06T09:35:42Z | - |
dc.date.issued | 2010 | - |
dc.identifier | doi: 10.1007/s00277-009-0864-x | - |
dc.identifier | issn: 0939-5555 | - |
dc.identifier | e-issn: 1432-0584 | - |
dc.identifier.citation | Annals of Hematology 89(5): 453-458 (2010) | - |
dc.identifier.uri | http://hdl.handle.net/10261/59519 | - |
dc.description.abstract | We have analyzed brain and acute leukemia, cytoplasmic (BAALC) gene expression and other genetic markers (ERG, EVI1, MN1, PRAME, WT1, FLT3, and NPM1 mutations) in 127 intermediate-risk acute myeloid leukemia (AML) patients: 98 cytogenetically normal and 29 with intermediate-risk cytogenetic alterations. High versus low BAALC expressers showed a higher refractoriness to induction treatment (31% vs 10%; p∈=∈.005), lower complete remission rate after salvage therapy (82% vs 97%; p∈=∈.010), and lower 3-year overall (23% vs 58%, p∈<∈.001) and relapse-free survival (26% vs 52%, p∈=∈.006). Similar results were found when cytogenetic subgroups were analyzed separately. Multivariate models confirmed the unfavorable prognosis of this marker. In conclusion, BAALC is a relevant prognostic marker in intermediate-risk AML. © 2009 Springer-Verlag. | - |
dc.description.sponsorship | This work has been partially supported by the grants PI061351 and 00/0023-00 from the Spanish “Fondo de Investigaciones Sanitarias de la Seguridad Social”, 89/A/06 from “Gerencia Regional de Salud, Junta Castilla y León”, and CIC, IBMCC (USAL-CSIC), Spain. | - |
dc.language.iso | eng | - |
dc.publisher | Springer Nature | - |
dc.rights | closedAccess | - |
dc.title | BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML) | - |
dc.type | artículo | - |
dc.identifier.doi | 10.1007/s00277-009-0864-x | - |
dc.date.updated | 2012-11-06T09:35:42Z | - |
dc.description.version | Peer Reviewed | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.openairetype | artículo | - |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
40
checked on 10-abr-2024
WEB OF SCIENCETM
Citations
36
checked on 28-feb-2024
Page view(s)
394
checked on 23-abr-2024
Download(s)
115
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.